New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Where the cash went Fiscal 2026, year to Jun 30, 2026

Free cash flow was −$35.8M: capital expenditures were more than operating cash flow. Cash fell by $17.0M. What is a cash flow statement?

Free cash flow
−$35.8M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$17.0M over the period
Where the cash went, in millions of dollars
Operating cash flow−35.8
Free cash flow−35.8
Shares issued, net+24.0
Other−5.1
Change in cash−17.0

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Jun '24 Jun '25 Jun '26
Net Income
(31.44) (24.83) (38.65)
Operating Cash Flow
(15.07) (23.73) (35.82)
Investing cash flow
— 1.15 (3.68)
Financing cash flow
19.59 29.42 22.65
Ending Cash
12.18 18.86 2.81
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026